Cancer immunotherapy approved in UK


Sign up online today & collaborate

or click here to find out more

Cancer immunotherapy approved in UK

Date: 02/07/ 2015

A pioneering cancer drug that harnesses the power of the immune system has been approved for use in the UK.

Nivolumab was one of the drugs labelled a "milestone" therapy at a major cancer conference last month.

It has now been approved through the UK's Early Access to Medicines Scheme, which fast-tracks promising new therapies.

The drug has been shown to stop skin and lung cancers from progressing, in clinical trials.

Enhanced defence

The immune system is a powerful defence against infection. However, there are many "brakes" built in to stop the system attacking its own tissues.

Cancer - which is a corrupted version of healthy tissue - can take advantage of these brakes to evade assault from the immune system.

Nivolumab takes the brakes off.

For more click here

Source: BBC

© Catalyst Innovation Portal 2019